<?xml version='1.0' encoding='utf-8'?>
<document id="24727322"><sentence text="P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice." /><sentence text="To clarify the role of ABCB1, ABCG2, and CYP3A in blood and brain exposure of everolimus using knockout mouse models"><entity charOffset="78-88" id="DDI-PubMed.24727322.s2.e0" text="everolimus" /></sentence><sentence text="" /><sentence text="We used wild-type, Abcb1a/1b(-/-), Abcg2(-/-), Abcb1a/1b;Abcg2(-/-), and Cyp3a(-/-) mice to study everolimus oral bioavailability and brain accumulation" /><sentence text="" /><sentence text="Following everolimus administration, brain concentrations and brain-to-liver ratios were substantially increased in Abcb1a/1b(-/-)and Abcb1a/1b;Abcg2(-/-), but not Abcg2(-/-)mice"><entity charOffset="10-20" id="DDI-PubMed.24727322.s6.e0" text="everolimus" /></sentence><sentence text=" The fraction of everolimus located in the plasma compartment was highly increased in all knockout strains"><entity charOffset="17-27" id="DDI-PubMed.24727322.s7.e0" text="everolimus" /></sentence><sentence text=" In vitro, everolimus was rapidly degraded in wild-type but not knockout plasma"><entity charOffset="11-21" id="DDI-PubMed.24727322.s8.e0" text="everolimus" /></sentence><sentence text=" Carboxylesterase 1c (Ces1c), a plasma carboxylesterase gene, was highly upregulated (âˆ¼80-fold) in the liver of knockout mice relative to wild-type mice, and plasma Ces1c likely protected everolimus from degradation by binding and stabilizing it"><entity charOffset="188-198" id="DDI-PubMed.24727322.s9.e0" text="everolimus" /></sentence><sentence text=" This binding was prevented by preincubation with the carboxylesterase inhibitor BNPP" /><sentence text=" In vivo knockdown experiments confirmed the involvement of Ces1c in everolimus stabilization"><entity charOffset="69-79" id="DDI-PubMed.24727322.s11.e0" text="everolimus" /></sentence><sentence text=" Everolimus also markedly inhibited the hydrolysis of irinotecan and p-nitrophenyl acetate by mouse plasma carboxylesterase and recombinant human CES2, respectively"><entity charOffset="54-64" id="DDI-PubMed.24727322.s12.e0" text="irinotecan" /><entity charOffset="69-90" id="DDI-PubMed.24727322.s12.e1" text="p-nitrophenyl acetate" /><pair ddi="false" e1="DDI-PubMed.24727322.s12.e0" e2="DDI-PubMed.24727322.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24727322.s12.e0" e2="DDI-PubMed.24727322.s12.e1" /></sentence><sentence text=" After correcting for carboxylesterase binding, Cyp3a(-/-), but not Abcb1a/1b(-/-), Abcg2(-/-), or Abcb1a/1b;Abcg2(-/-)mice, displayed highly (&gt;5-fold) increased oral availability of everolimus"><entity charOffset="183-193" id="DDI-PubMed.24727322.s13.e0" text="everolimus" /></sentence><sentence text="" /><sentence text="Brain accumulation of everolimus was restricted by Abcb1, but not Abcg2, suggesting the use of coadministered ABCB1 inhibitors to improve brain tumor treatment"><entity charOffset="22-32" id="DDI-PubMed.24727322.s15.e0" text="everolimus" /></sentence><sentence text=" Cyp3a, but not Abcb1a/1b, restricted everolimus oral availability, underscoring drug-drug interaction risks via CYP3A"><entity charOffset="38-48" id="DDI-PubMed.24727322.s16.e0" text="everolimus" /></sentence><sentence text=" Upregulated Ces1c likely mediated the tight binding and stabilization of everolimus, causing higher plasma retention in knockout strains"><entity charOffset="74-84" id="DDI-PubMed.24727322.s17.e0" text="everolimus" /></sentence><sentence text=" This Ces upregulation might confound other pharmacologic studies" /><sentence text="" /></document>